SONN Fundamental Analysis - SONNET BIOTHERAPEUTICS HOLDI

Fundamental Rating

Overall SONN gets a fundamental rating of 2 out of 10. We evaluated SONN against 559 industry peers in the Biotechnology industry. While SONN seems to be doing ok healthwise, there are quite some concerns on its profitability. SONN is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

SONN had negative earnings in the past year.

In the past year SONN has reported a negative cash flow from operations.

SONN had negative earnings in each of the past 5 years.

In the past 5 years SONN always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -346.31%, SONN is doing worse than 94.45% of the companies in the same industry.

The Return On Equity of SONN (-2006.04%) is worse than 83.36% of its industry peers.

		Industry Rank	Sector Rank
ROA	-346.31%
ROE	-2006.04%
ROIC	N/A

ROA(3y)-375.01%

ROA(5y)-253.56%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SONN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SONN does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, SONN has more shares outstanding

The number of shares outstanding for SONN has been increased compared to 5 years ago.

There is no outstanding debt for SONN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -56.24, we must say that SONN is in the distress zone and has some risk of bankruptcy.

SONN has a worse Altman-Z score (-56.24) than 94.10% of its industry peers.

SONN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-56.24

ROIC/WACCN/A

WACC9.62%

2.3 Liquidity

A Current Ratio of 1.03 indicates that SONN should not have too much problems paying its short term obligations.

SONN's Current ratio of 1.03 is on the low side compared to the rest of the industry. SONN is outperformed by 87.30% of its industry peers.

SONN has a Quick Ratio of 1.03. This is a normal value and indicates that SONN is financially healthy and should not expect problems in meeting its short term obligations.

SONN has a worse Quick ratio (1.03) than 86.05% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.03
Quick Ratio	1.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

SONN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 71.39%, which is quite impressive.

Looking at the last year, SONN shows a very strong growth in Revenue. The Revenue has grown by 942.75%.

Measured over the past years, SONN shows a very negative growth in Revenue. The Revenue has been decreasing by -77.28% on average per year.

EPS 1Y (TTM)71.39%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-258.93%

Revenue 1Y (TTM)942.75%

Revenue growth 3Y-66.16%

Revenue growth 5Y-77.28%

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y68.91%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SONN. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SONN. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SONN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SONNET BIOTHERAPEUTICS HOLDI

NASDAQ:SONN (6/11/2025, 8:19:41 PM)

1.1701

-0.01 (-0.84%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)05-13 2025-05-13/bmo

Earnings (Next)08-12 2025-08-12

Inst Owners3.06%

Inst Owner Change81.05%

Ins Owners1.54%

Ins Owner Change0%

Market Cap3.71M

Analysts82.86

Price Target20.4 (1643.44%)

Short Float %3.14%

Short Ratio2.37

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-2.44%

Min EPS beat(2)-10.03%

Max EPS beat(2)5.16%

EPS beat(4)3

Avg EPS beat(4)9.35%

Min EPS beat(4)-10.03%

Max EPS beat(4)31.98%

EPS beat(8)6

Avg EPS beat(8)20.41%

EPS beat(12)9

Avg EPS beat(12)18.77%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)37.97%

EPS NY rev (1m)0%

EPS NY rev (3m)-1.17%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	3.71
P/FCF	N/A
P/OCF	N/A
P/B	5.6
P/tB	5.6
EV/EBITDA	N/A

EPS(TTM)-11.88

EYN/A

EPS(NY)-3.53

Fwd EYN/A

FCF(TTM)-3.67

FCFYN/A

OCF(TTM)-3.67

OCFYN/A

SpS0.32

BVpS0.21

TBVpS0.21

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-346.31%
ROE	-2006.04%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-375.01%

ROA(5y)-253.56%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0.26

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	19.83%
Cap/Sales	2.4%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.03
Quick Ratio	1.03
Altman-Z	-56.24

F-Score4

WACC9.62%

ROIC/WACCN/A

Cap/Depr(3y)3199.76%

Cap/Depr(5y)1924.96%

Cap/Sales(3y)207.2%

Cap/Sales(5y)124.63%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)71.39%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-258.93%

EPS Next Y68.91%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)942.75%

Revenue growth 3Y-66.16%

Revenue growth 5Y-77.28%

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-8.79%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-468%

EBIT Next 3Y-90.14%

EBIT Next 5Y-41.82%

FCF growth 1Y54.28%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y52.76%

OCF growth 3YN/A

OCF growth 5YN/A

SONNET BIOTHERAPEUTICS HOLDI (SONN) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens